It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback